Forbion
Overview
Forbion is a global venture capital firm with deep expertise in Europe, investing in innovative biotech companies across all stages of pharmaceutical drug development.
Classification
- Headquarters
- Nijmegen, Netherlands
- Geographic focus
- EU + US
- Stage
- any
- Current fund
- Fund II
- Portfolio
- 6 companies
Fund details
- Fund size
- €890m
- AUM
- €5B+
- Lead rate
- 88%
- Founded
- 2000
Signals graph-derived
Thesis & focus
biotech expertise
Capstan Therapeutics (sold to AbbVie for $2.1bn), RAPT Therapeutics (acquired by GSK for $2.2bn), Gyroscope Therapeutics (sold to Novartis for up to $1.5bn)
innovative biotech companies, (bio-) pharmaceutical drug development across all stages; rare genetic diseases
Aims to be a beacon of hope for patients living with severe rare genetic diseases and their families; team consists of over 50 people of diverse nationalities across three offices in The Netherlands, Germany and the US.
Investment thesis
Forbion is a global venture capital firm dedicated to advancing groundbreaking biotech innovations and sustainable solutions that improve the health of people and our planet. They invest in innovative biotech companies, leveraging deep expertise in Europe.
Portfolio companies
No portfolio companies linked yet.
Co-investors
Loading co-investment network…
No co-invest data available.
Source: vc_export
Website preview visit ↗
